

Beyond Model Informed Drug Development: How Model Integrated Evidence is turning supportive analysis into primary evidence

A KEY QUESTION



How can Model Integrated Evidence help to eliminate white space in pharmaceutical R&D?

KEYWORDS

Model Informed Drug Development (MIDD), Model Integrated Evidence (MIE), Pharmaceutical R&D, Evidence Gaps (white space), Clinical Trial Design, Quantitative Modeling, PK/PD, Regulatory Acceptance, Decision Making



For more than two decades, Model Informed Drug Development (MIDD) has played an increasingly important role in pharmaceutical research and development. By applying mathematical and statistical models to preclinical and clinical data, MIDD has helped sponsors improve dose selection, optimize study design and make more confident development decisions.

A brief evolution of MIDD

The foundations of MIDD trace back to the earliest days of pharmacology, when drug effects were observed empirically and interpreted through exposure–response relationships. Over time, advances in analytical science enabled the emergence of pharmacokinetics (PK), pharmacodynamics (PD), population PK, PK/PD modeling and physiologically based pharmacokinetic (PBPK) approaches.

As computational power and data availability increased, these methods evolved into what is now recognized as MIDD: the systematic use of models to inform development strategy and regulatory decision making. Today, MIDD is widely accepted by regulators and sponsors alike as a valuable tool for interpreting data, reducing uncertainty and supporting key development decisions. However, its role has traditionally remained supportive rather than evidentiary.

Where traditional approaches fall short

Despite the success of MIDD, many development challenges persist. Conventional clinical trials can be large, costly and slow to deliver answers. These limitations are particularly evident in rare diseases, pediatric development, under served populations and scenarios where it is impractical or unethical to generate extensive clinical datasets. In these settings, traditional evidence requirements can restrict progress even when strong scientific rationale and modelling insights exist. As a result, sponsors are often left with gaps in evidence, white space, where important decisions must be made despite incomplete or inefficiently generated data.

Introducing Model Integrated Evidence (MIE)

Model Integrated Evidence (MIE) represents the next stage in the evolution of model based drug development. Rather than using models solely to interpret clinical data, MIE treats model derived results as evidence in their own right. In this paradigm, validated models generate data that can be integrated with, or in some cases, substitute for traditional clinical evidence. MIE extends the principles of MIDD by enabling optimization, extrapolation, augmentation and substitution of clinical data through modeling. Simulated data may be blended with observed data or used to support decisions in previously unstudied populations or clinical contexts. This shift moves models beyond analytical tools to play a central role in generating evidence that can inform development decisions.


Regulatory momentum and growing confidence

Importantly, MIE is not a theoretical concept. Regulatory agencies have increasingly discussed the role of advanced modeling in supporting development and regulatory decisions. Over recent years, regulatory guidance and pilot programs have signaled growing openness to model generated evidence when it is scientifically justified, transparently developed and appropriately validated.

This evolving regulatory landscape reflects increased confidence in both the science underpinning quantitative models and the governance frameworks used to develop and apply them.

What MIE changes for drug developers

By integrating models directly into the evidentiary framework, MIE has the potential to support more efficient development timelines, reduce reliance on less efficient clinical trials designs and enhance decision-making confidence. It offers value in early phase development, dose optimization and situations where conventional trial designs struggle to deliver timely or representative data. More broadly, MIE provides a structured approach to replacing white space with scientifically robust evidence, enabling sponsors to advance programs more efficiently while maintaining rigorous standards of safety and efficacy.



Looking ahead: From insight to evidence

The continued evolution of MIDD and MIE will depend on collaboration across industry, regulators, technology providers and academia. Advances in artificial intelligence, machine learning and model standardization are expected to further expand the role of modeling in development. As these approaches mature, the distinction between “supportive analysis” and “primary evidence” is likely to continue to blur. The vision is clear: a future in which model integrated evidence is treated as a core component of drug development, helping eliminate white space, accelerate R&D and ultimately deliver better therapies to patients sooner.

LEARN MORE at fortrea.com

Disclaimer

This article reflects the author's perspective and is provided for informational purposes only. It does not constitute regulatory, clinical or operational advice. Approaches and outcomes may vary depending on program design, governance and execution context.